Evidence map›Paper›PMID 39745872›Full record

ArticleMolecular biology of the cell2025

Parkinson disease-associated toxic exposures selectively up-regulate vesicular glutamate transporter vGlut2 in a model of human cortical neurons.

Karis A Clark, Andrew J White, Wojciech Paslawski, Kellianne D Alexander, Shaoning Peng, Tracy L Young-Pearse, Per Svenningsson, Dennis J Selkoe, Gary P H Ho

Abstract read
In one paragraph

Article in Molecular biology of the cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karis A ClarkAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Andrew J WhiteAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Wojciech PaslawskiDepartment of Clinical Neuroscience, Karolinska Institute, 17176 Stockholm, Sweden.
Kellianne D AlexanderAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Shaoning PengAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Tracy L Young-PearseAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Per SvenningssonDepartment of Clinical Neuroscience, Karolinska Institute, 17176 Stockholm, Sweden.
Dennis J SelkoeAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
Gary P H HoAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.ORCID 0000-0001-7004-8630

Funding

Probing Heterogeneity of Alzheimer's Disease Using iPSCsR01AG055909 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Tracy L YOUNG-PEARSE · 2018 to 2026
$5.7M
Biology of Native Alpha-Synuclein Tetramers in Parkinson's DiseaseRF1NS083845 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SELKOE, DENNIS J · 2020 to 2020
$2.9M
Protein Palmitoylation in Synuclein PathophysiologyK08NS110876 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, GARY P. H. · 2019 to 2023
$1.0M
Defining The Substrates of Acyl Protein Thioesterase-1: Their Role in Modulating Alpha-Synuclein ToxicityR21NS136895 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI HO, GARY P. H. · 2024 to 2025
$442k
NIA NIH HHS R01 AG055909NINDS NIH HHS K08 NS110876NINDS NIH HHS R21 NS136895NINDS NIH HHS RF1 NS083845
6 · The paper itself

Abstract

Parkinson disease (PD) is the second most common neurodegenerative disease, characterized by both motor and cognitive features. Motor symptoms primarily involve midbrain dopaminergic neurons, while cognitive dysfunction involves cortical neurons. Environmental factors are important contributors to PD risk. In rodents, rare midbrain dopaminergic neurons that coexpress the vesicular glutamate transporter 2 (vGlut2) are resistant to various toxins that induce dopaminergic neurodegeneration. However, it is unclear how, and with what degree of specificity, cortical glutamatergic neurons respond to PD-associated exposures with respect to vGlut2. Here, we found that vGlut2 in stem cell-derived human cortical-like glutamatergic neurons was up-regulated in a highly specific manner to certain PD-related chemicals, such as rotenone, but not others, such as paraquat. Further, exposure to recombinant preformed fibrils of alpha-synuclein (αS), a protein accumulating in PD, also increased vGlut2, while fibrils from non-PD-related proteins did not. This effect did not involve templated aggregation of endogenous αS. Finally, the knockdown of vGlut2 sensitized cortical neurons to rotenone, supporting a functional role in resilience. Thus, up-regulation of vGlut2 occurs in a highly selective manner in response to specific PD-associated exposures in a model of cortical glutamatergic neurons, a key cell type for understanding PD dementia.

Indexed as

NeuronsParkinson DiseaseVesicular Glutamate Transport Protein 2alpha-SynucleinCerebral CortexDopaminergic NeuronsHumansMesencephalonParaquatRotenoneUp-Regulationalpha-SynucleinParaquatRotenoneSLC17A6 protein, humanVesicular Glutamate Transport Protein 2

Identifiers

PMID39745872
PMCPMC11809304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.